| 영문 | complement | 한글 | 보체 |
|---|---|---|---|
| 설명 | 항체와 반응하여 항체와 결합된 세포의 파괴를 일으키는 단백질을 말한다. 항체가 항체와 결합한 세포를 파괴하는 방법에는 여러 가지가 있는데 그 중의 하나로 항체와 결합한 세포의 표면을 부분적으로 손상시켜 그 세포를 파괴하는 역할을 하는 것이 이 보체이다. 보체는 20가지의 단백질로 구성되어 있는데 약자로 C로 표시하며 각 종류를 나타낼 경우에는 C옆에 숫자를 써서 표시한다. |
||
| 영문 | complement fixation reaction | 한글 | 보체결합 반응, 도움체결합반응 |
|---|---|---|---|
| 설명 | 항체와의 반응에 있어서 보체와 결합하는 항체를 검사하는 방법으로, 이 반응은 최초에 기지항원, 피검혈청 및 보체를 혼합한다. 제2단계에서는 적혈구와 이것에 대응하는 용혈소의 혼합액을 가한다. 본 반응후 용혈이 일어나지 않으면 본체는 항원항체결합물에 결합한 것이 되어 양성이 되지만, 용혈이 일어난 경우 보체는 결합하지 않아 소비되지 않기 때문에 음성이 된다. 본 반응은 기지혈청을 써서 항원검출에 응용할 수 있으며, 마이코플라스마, 리케챠, 클라미디아, 바이러스, 매독 등의 진단에 쓰인다. |
||
| 영문 | test | 한글 | 검사 |
|---|---|---|---|
| 설명 | 어떤 다른 물질을 검출, 측정, 생성하기 위한 특정한 화학반응을 일으키는데 사용되는 방법. |
||
| 영문 | scratch test | 한글 | 난절법 |
|---|---|---|---|
| 설명 | 피부를 날카로운 바늘로 긁어 피부의 반응을 보는 검사로 피부 과민반응이나 알레르기를 알아보기 위한 검사이다. 바늘끝에 항원을 묻힌 뒤, 피부밑을 긁어 반응을 알아본다. 이때 항원이 아닌 대조물질(예를 들어 보통의 물)을 묻힌 바늘을 같이 반응하여 피부묘기증(dermographism) 단지 바늘의 긁힘만으로 알레르기 같은 반응을 일으키는 현상과 감별해야 한다. 난청, 청력소실(hearing loss) 청각이 저하 또는 상실된 상태. 원인과 정도는 여러 가지인데, 난청은 그 정도가 가장 심한 상태이다. 청각의 전도경로에 장애가 있을 때 난청이 일어나고, 그 병터가 외이도나 중이에 있는 것을 전음난청, 내이에 있는 것을 감음 난청이라 하여 구분한다. 또 병터의 자리를 명시하여 중이성 난청이나 미로성 난청 등으로 세분하기도 한다. |
||
| 영문 | stool guaiac test | 한글 | 대변 구아이악 검사 |
|---|---|---|---|
| 설명 | 대변내에 있을 수 있는 잠혈(눈에 보이지 않는 출혈)유무를 검사하는 방법으로, 혈구내의 heme peroxidase에 의해 guaiac이 산화되는 반응을 이용하여 측정한다. 방법은 3일간에 걸쳐 한 변에서 2군데씩 채취하여 검사한다. 위양성 반응(거짓으로 혈액이 있다고 나타나는 반응)은 식물 과산화효소를 함유하고 있는 홍당무의 섭취나 혈구 성분을 함유하고 있는 고기 섭취 등에서 나타날 수 있으며, 위음성 반응(실제로 혈액은 있지만, 혈액이 없다고 나타나는 반응)은 환원력을 가지고 있는 비타민 C의 복용시 나타날 수 있다. 특히 위양성 반응이 매우 흔하다. |
||
| PCT | peripheral carcinoid tumor; plasma clotting time; plasmacrit test; plasmacytoma; polychlorinated tri... |
|---|---|
| PAT | Pain Apperception Test; paroxysmal atrial tachycardia; patient; phenylaminotetrazole; physical abili... |
| AGCT | antiglobulin consumption test; Army General Classification Test |
| CAT | California Achievement Test; capillary agglutination test; catalase; cataract; catecholamine; Childr... |
| TAT | tetanus antitoxin; thematic apperception test; thematic aptitude test; thrombin-antithrombin complex... |
| CF | Complement Fixation Test |
|---|---|
| CFT | Complement Fixation Test |
| EPOC | Excess post-exercise oxygen consumption |
| FC | Feed consumption |
| MVO2 | Myocardial O2 consumption |
| consumption | 1. The using up of something, especially the rate at which it is used. 2. Obsolete term for a wasting of the tissues of the body, usually tuberculous. Origin: L. Con-sumo, pp. -sumptus, to take up wholly, use up, waste (05 Mar 2000) |
|---|---|
| consumption coagulopathy | <haematology> A disorder that includes accelerated platelet consumption with coagulation factor depletion (prolongation of PT and PTT) and stimulation of fibrinolysis (generation of fibrin split products). Disseminated intravascular coagulation can be caused by severe bacterial infections (sepsis), extensive burns, trauma, retained dead foetus, heatstroke, mismatched blood transfusion, metastatic cancer and some forms of leukaemia. Manifests with severe bleeding and bruising. Origin: Gr. Pathos = disease (27 Sep 1997) |
| oxygen consumption | The rate at which oxygen is used by a tissue; microliters of oxygen stpd used per milligram of tissue per hour; the rate at which oxygen enters the blood from alveolar gas, equal in the steady state to the consumption of oxygen by tissue metabolism throughout the body. (12 Dec 1998) |
| complement-fixation test | An immunological test for determining the presence of a particular antigen or antibody when one of the two is known to be present, based on the fact that complement is "fixed" in the presence of antigen and its specific antibody. See: Bordet-Gengou phenomenon. (05 Mar 2000) |
| male chromosome complement | The large majority of males have a 46, xy chromosome complement (46 chromosomes including an x and a y chromosome). A minority of males have other chromosome constitutions such as 47,xxy (47 chromosomes including two x chromosomes and a y chromosome) and 47,xyy (47 chromosomes including an x and two y chromosomes). (12 Dec 1998) |
| genetic complement | <biology, genetics> The set of chromosomes contained within any one particular cell. (07 May 1998) |
| receptors, complement | Molecules on the surface of some B-lymphocytes and macrophages, that recognise and combine with the c3b, c3d, c1q, and c4b components of complement. (12 Dec 1998) |
| receptors, complement 3b | Molecular sites on or in some B-lymphocytes and macrophages that recognise and combine with complement 3b. The primary structure of these receptors reveal that they contain transmembrane and cytoplasmic domains, with their extracellular portion composed entirely of thirty short consensus repeats each having 60 to 70 amino acids. (12 Dec 1998) |
| receptors, complement 3d | Molecular sites on or in B-lymphocytes, follicular dendritic cells, lymphoid cells, and epithelial cells that recognise and combine with complement 3d. Human cr2 serves as a receptor for both c3dg and the gp350/220 glycoprotein of herpes virus 4, human, and binds the monoclonal antibody okb7, which blocks binding of both ligands to the receptor. (12 Dec 1998) |
| chromosome complement | The whole set of chromosomes for the species. In humans, the chromosome complement (which is also called the karyotype) consists of 46 chromosomes. (12 Dec 1998) |
| complement | <immunology> A term originally used to refer to the heat labile factor in serum that causes immune cytolysis, the lysis of antibody coated cells and now referring to the entire functionally related system comprising at least 20 distinct serum proteins that is the effector not only of immune cytolysis but also of other biologic functions. Complement activation occurs by two different sequences, the classic and alternative pathways. The proteins of the classic pathway are termed components of complement and are designated by the symbols C1 through C9. C1 is a calcium dependent complex of three distinct proteins C1q, C1r and C1s. The proteins of the alternative pathway (collectively referred to as the properdin system) and complement regulatory proteins are known by semisystematic or trivial names. Fragments resulting from proteolytic cleavage of complement proteins are designated with lower case letter suffixes, for example, C3a. Inactivated fragments may be designated with the suffix i, for example C3bi. Activated components or complexes with biological activity are designated by a bar over the symbol for example C1 or C4b, 2a. The classic pathway is activated by the binding of C1 to classic pathway activators, primarily antigen-antibody complexes containing IgM, IgG1, IgG3, C1q binds to a single IgM molecule or two adjacent IgG molecules. The alternative pathway can be activated by IgA immune complexes and also by nonimmunologic materials including bacterial endotoxins, microbial polysaccharides and cell walls. Activation of the classic pathway triggers an enzymatic cascade involving C1, C4, C2 and C3, activation of the alternative pathway triggers a cascade involving C3 and factors B, D and P. Both result in the cleavage of C5 and the formation of the membrane attack complex. Complement activation also results in the formation of many biologically active complement fragments that act as anaphylatoxins, opsonins or chemotactic factors. (05 Jan 1998) |
| complement 1 | The first complement component to act in the cytolysis reaction. It is a trimolecular complex held together with ca ions and when activated, has esterase activity which initiates the next step in the sequence. (12 Dec 1998) |
| complement 1 inactivators | Compounds which inhibit, antagonise, or inactivate complement 1. A well-known inhibitor is a serum glycoprotein believed to be alpha-2-neuroaminoglycoprotein. It inhibits the activated (esterase) form of complement 1 as well as kinin-forming, coagulation, and fibrinolytic systems. Deficiency of this inactivator has been found in patients with hereditary angioneurotic oedema. These compounds are members of the serpin superfamily. (12 Dec 1998) |
| complement 1q | <chemical> Subcomponent of complement 1 (c1) which recognises and binds to the heavy chain of IgG or IgM initiating the classical complement pathway. The interaction of c1q and immunoglobulin activates c1r and c1s. The activated c1r and c1s molecules are cleaved off the complex by c1-inhibitor, allowing the collagen-like region of c1q to become accessible for interaction with cell membrane c1q receptors. Chemical name: Complement C1q (12 Dec 1998) |
| complement 1r | <enzyme> Subcomponent of complement 1 which, when activated by c1q, activates subcomponent c1s by proteolytic cleavage. Registry number: EC 3.4.21.41 (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|